

CLAIMS

*Just*  
1. A method for treatment of neurological or immunological disorders in a patient comprising the step of stimulating secretion of pancreatic juices in said patient.

2. The method of claim 2 wherein the step of stimulating secretion of pancreatic juices comprises the step of administering to said patient an effective amount of secretin.

3. The method of claim 2 wherein said effective amount of secretin is administered by infusion.

4. The method of claim 3 wherein administering said effective amount of secretin by infusion includes the step of intravenously infusing secretin in an amount of about 2 clinical units (CU) per kilogram (kg) of body weight.

5. The method of claim 2 wherein said effective amount of secretin is administered transdermally.

6. The method of claim 5 wherein administering said effective amount of secretin transdermally includes the steps of:  
applying a transdermal carrier substance to a portion of the skin of said patient; and  
applying crystalline secretin in said effective amount onto said transdermal carrier substance.

1 7. The method of claim 6 wherein said transdermal carrier  
2 substance includes dimethyl sulfoxide (DMSO).

1 8. The method of claim 6 wherein said effective amount of  
2 secretin includes between 5 and 20 clinical units (CU) of  
3 crystalline secretin per dose.

1 9. The method of claim 6 wherein said transdermal carrier  
2 substance is selected from the group consisting of a gel and a  
3 lotion.

1 10. The method of claim 5 wherein administering secretin  
2 transdermally includes administering said effective amount of  
3 secretin with a patch to be applied to a portion of the skin of  
4 said patient.

1 11. The method of claim 5 wherein administering secretin  
2 transdermally includes administering said effective amount of  
3 secretin using acoustic waves causing said secretin to permeate a  
4 skin surface of said patient.

1 12. The method of claim 2 wherein said effective amount of  
2 secretin is administered orally.

1 13. The method of claim 12 wherein said effective amount of  
2 secretin is administered orally using an oral carrier selected  
3 from the group consisting of a tablet, capsule or lozenge.

1 14. The method of claim 2 wherein said effective amount of  
2 secretin is administered using a suppository.

1 15. The method of claim 2 wherein said effective amount of  
2 secretin is administered by inhalation.

1 16. The method of claim 2 wherein said neurological  
2 disorders include autistic spectrum disorders.

1 17. The method of claim 2 wherein said effective amount of  
2 secretin includes an amount of secretin sufficient to increase  
3 serotonin levels in the brain of said patient.

1 18. The method of claim 1 wherein stimulating secretion of  
2 said pancreatic juices increases at least one neuropeptide  
3 hormone select from the group consisting of serotonin, dopamine  
4 and CCK levels in said patient.

1 19. The method of claim 1 wherein the step of stimulating  
2 secretion of pancreatic juices includes the step of causing  
3 secretion of an effective amount of secretin in said patient.

1 20. The method of claim 19 wherein the step of causing  
2 secretion of an effective amount of secretin in said patient  
3 includes stimulating the duodenum of said patient to produce  
4 secretin.

1 21. A composition for treatment neurological or  
2 immunological disorders in a patient comprising an effective  
3 amount of secretin and a physiologically acceptable carrier.

1 22. The composition of claim 21 wherein said  
2 physiologically acceptable carrier includes a transdermal carrier  
3 substance.

1 23. The composition of claim 22 wherein said transdermal  
2 carrier substance includes dimethyl sulfoxide (DMSO).

1 24. The composition of claim 23 wherein said effective  
2 amount of secretin includes about 15 clinical units (CU) of  
3 crystalline secretin per dose.

1 25. The composition of claim 21 wherein said  
2 physiologically acceptable carrier includes sodium chloride for  
3 dissolving said effective amount of secretin.

1 26. The composition of claim 25 wherein said effective  
2 amount of secretin includes about 2 clinical units (CU) per  
3 kilogram (kg) of body weight of said patient per dose.

1 27. The composition of claim 21 wherein said  
2 physiologically acceptable carrier includes an oral carrier.

1 28. The composition of claim 21 wherein said  
2 physiologically acceptable carrier includes an inhalable carrier.

1  
2

29. The composition of claim 21 wherein said composition is  
for the treatment of autism.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

1           30. A method for the treatment of autism comprising the  
2 step of administering to said patient an effective amount of  
3 secretin.

1           31. The method of claim 30 wherein said effective amount of  
2 secretin is administered by infusion.

1           32. The method of claim 31 wherein administering said  
2 effective amount of secretin by infusion includes the step of  
3 intravenously transfusing secretin in an amount of about 2  
4 clinical units (CU) per kilogram (kg) of body weight per dose.

1           33. The method of claim 30 wherein said effective amount of  
2 secretin is administered transdermally.

1           34. The method of claim 33 wherein administering said  
2 effective amount of secretin transdermally includes the steps of:  
3           applying a transdermal carrier substance to a portion of the  
4 skin of said patient; and  
5           applying crystalline secretin in said effective amount onto  
6 said transdermal carrier substance.

1           35. The method of claim 34 wherein said transdermal carrier  
2 substance includes dimethyl sulfoxide (DMSO).

1           36. The method of claim 35 wherein said effective amount of  
2 secretin includes about 15 clinical units (CU) of crystalline  
3 secretin per dose.